Araştırma Makalesi


DOI :10.26650/IUITFD.2021.849990   IUP :10.26650/IUITFD.2021.849990    Tam Metin (PDF)

MDR1 C3435T POLİMORFİZMİ: KOLOREKTAL KANSER RİSKİ İLE İLİŞKİSİ ÜZERİNE BİR ÖN ÇALIŞMA

Gülçin Özkaraİlhan YaylımSoykan ArıkanTurgay İsbirHülya Yılmaz Aydoğan

Amaç: Bir veya çoklu genetik mekanizmaların kombinasyonuyla oluşan heterojen bir hastalık olan kolorektal kanser (KRK) dünyada en sık görülen üçüncü kanserdir. P-glikoproteini (P-gp) kodlayan çoklu ilaç direnci geni-1 (Multiple drug resistance-1 (MDR1)) ilaçların biyoyararlanımı ve hücre toksisitesinde rol oynar. Bu çalışmada, Türk popülasyonunda MDR1 geni C3435T polimorfizmi ve KRK riski arasındaki olası ilişkiyi araştırmayı amaçladık. Gereç ve Yöntemler: Çalışmamıza KRK hastası (26 erkek, 17 kadın) 43 kişi ve 48 sağlıklı kontrol (34 erkek, 14 kadın) dahil edilmiştir. MDR1 C3435T genotipleri Restriksiyon Fragman Uzunluk Polimorfizmi RFUP) yöntemiyle belirlenmiştir. Bulgular: MDR1 C3435T genotiplerinin dağılımı açısından çalışma grupları arasında istatistiksel anlamlılık elde edilmiştir. KRK hasta grubunda MDR1 C3435T CC, TT ve CT genotiplerinin sıklığı sırasıyla %16,3, %32,6 ve %51,2 olarak bulunmuştur. Homozigot TT genotipi frekansı KRK hastalarında %32,6 bulunurken kontrollerde %14,6 (p=0,04; OR=2,82, 95% CI: 1,01-7,87) olarak tespit edilmiştir. Hastalar ve sağlıklı kontroller karşılaştırıldığında MDR1 C3435T polimorfizmi TT genotipi taşıyıcıları KRK gelişimi için 2,8 kat (p<0,05) artmış risk altında bulunmuştur. Sonuç: Sonuçlarımız MDR1 C3435T polimorfizminin Türk popülasyonunda KRK gelişimi için genetik risk faktörlerinden biri olabileceğini göstermektedir.

DOI :10.26650/IUITFD.2021.849990   IUP :10.26650/IUITFD.2021.849990    Tam Metin (PDF)

MDR1 C3435T POLYMORPHISM: A PRELIMINARY STUDY ON ITS RELATIONSHIP WITH THE RISK OF COLORECTAL CANCER

Gülçin Özkaraİlhan YaylımSoykan ArıkanTurgay İsbirHülya Yılmaz Aydoğan

Objective: Colorectal carcinoma (CRC) is the third most frequent cancer in the world and a heterogenious disease which aroze from one or a combination of different genetic mechanisms. The multiple drug resistance-1 (MDR1) gene which encodes P-glycoprotein (P-gp) plays a part in the bioavailability of drugs and cell toxicity. In the current study, we aimed to investigate the possible relation between the MDR1 gene C3435T polymorphism and CRC risk in the Turkish population. Material and Methods: Forty three patients (26 men, 17 women) with CRC and 48 healthy controls (34 men, 14 women) were included in the study. The MDR1 C3435T genotypes were determined by the Restriction Fragment Length Polymorphism (RFLP) method. Results: Statistical significance was obtained in terms of genotype distributions of MDR1 C3435T genotypes between study groups. The frequencies of MDR1 C3435T CC, TT and CT genotypes in the CRC patient group were found as 16.3%, 32.6% and 51.2%, respectively. The frequency of the homozygous TT genotype was found as 32.6% in CRC patients while it was identified as 14.6% in controls (p=0.04; OR=2.82, 95% CI: 1.01-7.87). When the patients were compared with the healthy population, TT genotype carriers of MDR1 C3435T polymorphism were found at 2.8-fold (p<0.05 ) increased risk for the development of CRC. Conclusion: Our results show that the MDR1 C3435T polymorphism might be one of the genetic risk factors for CRC development in the Turkish population.


PDF Görünüm

Referanslar

  • 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2018;68(6):394-424. [CrossRef] google scholar
  • 2. Bogaert J, Prenen H. Molecular genetics of colorectal cancer. Ann Gastroenterol 2014;27(1):9-14. google scholar
  • 3. Tariq K, Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med 2016;13(1):120-35. [CrossRef] google scholar
  • 4. Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 1996;192(7):768-80. [CrossRef] google scholar
  • 5. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258(5088):1650-4. [CrossRef] google scholar
  • 6. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2(1):48-58. [CrossRef] google scholar
  • 7. Jordan A, Scholz R. Selection and characterization of heat-resistant variants of multidrug-resistant human gastric carcinoma cell lines. Exp Oncol 2005;27(1):18-23. google scholar
  • 8. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003;22(47):7468-85. [CrossRef] google scholar
  • 9. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997;8(3):161-70. [CrossRef] google scholar
  • 10. Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2003;2(7):685-98. google scholar
  • 11. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97(7):3473-8. [CrossRef] google scholar
  • 12. Kurzawski M, Drozdzik M, Suchy J, Kurzawski G, Bialecka M, Gornik W, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol 2005;61(5-6):389-94. [CrossRef] google scholar
  • 13. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002;71(4):297-303. [CrossRef] google scholar
  • 14. Turgut S, Yaren A, Kursunluoglu R, Turgut G. MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res 2007;38(5):539-44. [CrossRef] google scholar
  • 15. Taheri M, Mahjoubi F, Omranipour R. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet Mol Res 2010;9(1):34-40. [CrossRef] google scholar
  • 16. Siegsmund M, Brinkmann U, Schâffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the P-glycoprotein transporter MDR1 (C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002;13(7):1847-54. [CrossRef] google scholar
  • 17. Baldissera VD, de Mattos AA, Corral GP, de Araujo FB, Marroni CA, de Mello Brandao AB, et al. Evaluation of the C3435T polymorphisim in the MDR1 gene in patients with hepatocellular carsinoma. Ann Hepatol 2012;11(6):899-906. [CrossRef] google scholar
  • 18. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ ABCB1.Drug Metab Pharmacokinet 2004;19(2):83-95. [CrossRef] google scholar
  • 19. Cascorbi I, Gerloff Th, Johne A, Meisel CH, Hoffmeyer S, Schwab M. Frequency ofsingle nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69(3):169-74. [CrossRef] google scholar
  • 20. Tan EK, Drozdzik M, Bialecka M, Honczarenko K, Klodowska-Duda G, Teo YY, et al. Analysis of MDR1 haplotypes in Parkinson’s disease in a white population. Neurosci Lett 2004;372(3):240-4. [CrossRef] google scholar
  • 21. Miller SA, Dykes DD, Polesky HS. Simples salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988;16(3):1215. [CrossRef] google scholar
  • 22. Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 2005;46(5):643-7. [CrossRef] google scholar
  • 23. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170):an important determinant in gastrointestinal disease. Gut 2003;52(5):759-66. [CrossRef] google scholar
  • 24. Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit 2000;22(1):137-40. [CrossRef] google scholar
  • 25. Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, et al. Functional C3435T polymorphism of MDR1 gene:an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004;72(5):314-21. [CrossRef] google scholar
  • 26. Illmer T, Schuler US, Thiede C, Schwarz UI, Kim RB, Gotthard S, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002;62(17):4955-62. google scholar
  • 27. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53(5):526-34. [CrossRef] google scholar
  • 28. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit 2004;26(2):180-5. [CrossRef] google scholar
  • 29. Jelen AM, Salagacka A, Zebrowska MK, Mirowski M, Talarowska M, Galecki P, et al. The influence of C3435T polymorphism of the ABCB1 gene on genetic susceptibility to depression and treatment response in Polish population Preliminary Report. Int J Med Sci 2015;12(12):974-9. [CrossRef] google scholar
  • 30. Humeny A, Rodel F, Rodel C, Sauer R, Fuzesi L, Becker C. MDR1 single nucleotide polymorphism C3435T in normal colorectal tissue and colorectal carcinomas detected by MALDI-TOF mass spectrometry. Anticancer Res 2003;23(3B):2735-40. google scholar
  • 31. Zhao L, Li K, Li W, Yang Z. Association between the C3435T polymorphism of ABCB1/MDR1 gene (rs1045642) and colorectal cancer susceptibility. Tumor Biol 2013;34 (3):1949-57. [CrossRef] google scholar
  • 32. Jin SS, Song WJ. Association between MDR1 C3435T polymorphism and colorectal cancer risk: A meta-analysis. Medicine (Baltimore) 2017;96(51):e9428. [CrossRef] google scholar
  • 33. Özhan G, Kara M, Sari FM, Yanar HT, Ercan G, Alpertunga B. Associations between the functional polymorphisms in the ABCB1 transporter gene and colorectal cancer risk: a case-control study in Turkish population. Toxicology Mechanisms and Methods 2013;23(4):235-9. [CrossRef] google scholar
  • 34. Fu Q, Zhang G, Chen H, Zheng Y, Cheng J. Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk. Tumour Biol 2013;34(6):3721-9. [CrossRef] google scholar
  • 35. Zeng FR, Ling Y, Yang J, Tian XC, Yang X, Luo RC. X-ray repair cross-complementing group 1 Arg399Gln gene polymorphism and susceptibility to colorectal cancer:a meta-analysis. Tumour Biol 2013;34(1):555-63. [CrossRef] google scholar
  • 36. Wang J, Wang B, Bi J, Li K, Di J. MDR1 gene C3435T polymorphism and cancer risk: a meta-analysis of 34 case-control studies. J Cancer Res Clin Oncol 2012;138(6):979-89. [CrossRef] google scholar

Atıflar

Biçimlendirilmiş bir atıfı kopyalayıp yapıştırın veya seçtiğiniz biçimde dışa aktarmak için seçeneklerden birini kullanın


DIŞA AKTAR



APA

Özkara, G., Yaylım, İ., Arıkan, S., İsbir, T., & Yılmaz Aydoğan, H. (2021). MDR1 C3435T POLİMORFİZMİ: KOLOREKTAL KANSER RİSKİ İLE İLİŞKİSİ ÜZERİNE BİR ÖN ÇALIŞMA. İstanbul Tıp Fakültesi Dergisi, 84(4), 531-536. https://doi.org/10.26650/IUITFD.2021.849990


AMA

Özkara G, Yaylım İ, Arıkan S, İsbir T, Yılmaz Aydoğan H. MDR1 C3435T POLİMORFİZMİ: KOLOREKTAL KANSER RİSKİ İLE İLİŞKİSİ ÜZERİNE BİR ÖN ÇALIŞMA. İstanbul Tıp Fakültesi Dergisi. 2021;84(4):531-536. https://doi.org/10.26650/IUITFD.2021.849990


ABNT

Özkara, G.; Yaylım, İ.; Arıkan, S.; İsbir, T.; Yılmaz Aydoğan, H. MDR1 C3435T POLİMORFİZMİ: KOLOREKTAL KANSER RİSKİ İLE İLİŞKİSİ ÜZERİNE BİR ÖN ÇALIŞMA. İstanbul Tıp Fakültesi Dergisi, [Publisher Location], v. 84, n. 4, p. 531-536, 2021.


Chicago: Author-Date Style

Özkara, Gülçin, and İlhan Yaylım and Soykan Arıkan and Turgay İsbir and Hülya Yılmaz Aydoğan. 2021. “MDR1 C3435T POLİMORFİZMİ: KOLOREKTAL KANSER RİSKİ İLE İLİŞKİSİ ÜZERİNE BİR ÖN ÇALIŞMA.” İstanbul Tıp Fakültesi Dergisi 84, no. 4: 531-536. https://doi.org/10.26650/IUITFD.2021.849990


Chicago: Humanities Style

Özkara, Gülçin, and İlhan Yaylım and Soykan Arıkan and Turgay İsbir and Hülya Yılmaz Aydoğan. MDR1 C3435T POLİMORFİZMİ: KOLOREKTAL KANSER RİSKİ İLE İLİŞKİSİ ÜZERİNE BİR ÖN ÇALIŞMA.” İstanbul Tıp Fakültesi Dergisi 84, no. 4 (Jan. 2022): 531-536. https://doi.org/10.26650/IUITFD.2021.849990


Harvard: Australian Style

Özkara, G & Yaylım, İ & Arıkan, S & İsbir, T & Yılmaz Aydoğan, H 2021, 'MDR1 C3435T POLİMORFİZMİ: KOLOREKTAL KANSER RİSKİ İLE İLİŞKİSİ ÜZERİNE BİR ÖN ÇALIŞMA', İstanbul Tıp Fakültesi Dergisi, vol. 84, no. 4, pp. 531-536, viewed 20 Jan. 2022, https://doi.org/10.26650/IUITFD.2021.849990


Harvard: Author-Date Style

Özkara, G. and Yaylım, İ. and Arıkan, S. and İsbir, T. and Yılmaz Aydoğan, H. (2021) ‘MDR1 C3435T POLİMORFİZMİ: KOLOREKTAL KANSER RİSKİ İLE İLİŞKİSİ ÜZERİNE BİR ÖN ÇALIŞMA’, İstanbul Tıp Fakültesi Dergisi, 84(4), pp. 531-536. https://doi.org/10.26650/IUITFD.2021.849990 (20 Jan. 2022).


MLA

Özkara, Gülçin, and İlhan Yaylım and Soykan Arıkan and Turgay İsbir and Hülya Yılmaz Aydoğan. MDR1 C3435T POLİMORFİZMİ: KOLOREKTAL KANSER RİSKİ İLE İLİŞKİSİ ÜZERİNE BİR ÖN ÇALIŞMA.” İstanbul Tıp Fakültesi Dergisi, vol. 84, no. 4, 2021, pp. 531-536. [Database Container], https://doi.org/10.26650/IUITFD.2021.849990


Vancouver

Özkara G, Yaylım İ, Arıkan S, İsbir T, Yılmaz Aydoğan H. MDR1 C3435T POLİMORFİZMİ: KOLOREKTAL KANSER RİSKİ İLE İLİŞKİSİ ÜZERİNE BİR ÖN ÇALIŞMA. İstanbul Tıp Fakültesi Dergisi [Internet]. 20 Jan. 2022 [cited 20 Jan. 2022];84(4):531-536. Available from: https://doi.org/10.26650/IUITFD.2021.849990 doi: 10.26650/IUITFD.2021.849990


ISNAD

Özkara, Gülçin - Yaylım, İlhan - Arıkan, Soykan - İsbir, Turgay - Yılmaz Aydoğan, Hülya. MDR1 C3435T POLİMORFİZMİ: KOLOREKTAL KANSER RİSKİ İLE İLİŞKİSİ ÜZERİNE BİR ÖN ÇALIŞMA”. İstanbul Tıp Fakültesi Dergisi 84/4 (Jan. 2022): 531-536. https://doi.org/10.26650/IUITFD.2021.849990



ZAMAN ÇİZELGESİ


Gönderim30.12.2020
Kabul27.05.2021
Çevrimiçi Yayınlanma29.09.2021

LİSANS


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


PAYLAŞ




İstanbul Üniversitesi Yayınları, uluslararası yayıncılık standartları ve etiğine uygun olarak, yüksek kalitede bilimsel dergi ve kitapların yayınlanmasıyla giderek artan bilimsel bilginin yayılmasına katkıda bulunmayı amaçlamaktadır. İstanbul Üniversitesi Yayınları açık erişimli, ticari olmayan, bilimsel yayıncılığı takip etmektedir.